论文部分内容阅读
目的探讨保留肾单位手术治疗肾癌的安全性及临床疗效。方法选取本院自2009年12月~2010年12月收治的42例行保留肾单位手术治疗的肾癌患者,对其临床资料进行回顾性分析。结果本组42例患者经保留肾单位手术治疗均取得成功,术后给予患者为期2年的随访,本组42例患者中仅1例患者发生远处转移死亡,占2.38%,1例患者在术后12个月后发生局部复发现象,占2.38%,给予其根治性肾切除术治疗后好转,2例患者术后发生暂时性肾功能不全现象,占4.76%。结论给予肾癌患者保留肾单位手术治疗可取得良好的效果,特别适于低分期小肾癌患者,临床效果显著,值得推广和应用。
Objective To investigate the safety and clinical efficacy of nephron sparing surgery in the treatment of renal cell carcinoma. Methods Forty-two patients with renal cell carcinoma who underwent nephron surgery were selected from December 2009 to December 2010 in our hospital. The clinical data of the patients were retrospectively analyzed. Results The 42 patients were treated by nephron-preserving surgery. All patients were followed up for 2 years. Only 1 of the 42 patients died of distant metastasis, accounting for 2.38%. One patient was in Local recurrence occurred after 12 months, accounting for 2.38%. After radical nephrectomy, the recurrence rate was improved, and transient renal insufficiency occurred in 2 patients (4.76%). Conclusion Renal cell carcinoma patients with renal cell surgery can retain good results, especially for patients with low-grade small renal cell carcinoma, the clinical effect is significant, it is worth promoting and application.